BHARAT BIOTECH INTERNATIONAL LIMITED

ICMR formalised MoAs with sponsors for Phase 1 Clinical Trials, marking entry into First-in-Human trials for four molecules. Collaborations include research on multiple myeloma, Zika vaccine, seasonal Influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukemia. This initiative aims to establish India as a leader in pharmaceutical agent clinical development.

ICMR formalizes agreements with sponsors for first-in-human phase 1 clinical trials, including research on multiple myeloma, Zika vaccine, seasonal Influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukaemia. This initiative aims to establish India as a leader in pharmaceutical agent clinical development and healthcare innovation.

ICMR formalizes MoAs with sponsors for phase 1 clinical trials of four molecules, aiming to establish India as a leader in pharmaceutical development. Collaborations include research on multiple myeloma, Zika vaccine, seasonal influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukaemia. Dr. Rajiv Bahl emphasizes ICMR's commitment to advancing clinical research through public-private partnerships, aligning with the government's vision of a 'Viksit Bharat'.

ICMR formalizes agreements with sponsors to advance first-in-human phase 1 clinical trials for four molecules, positioning India as a leader in healthcare innovation through strategic public-private partnerships.

ICMR signs MoAs with industry and academic partners for First-in-Human Phase 1 clinical trials of four molecules, marking a milestone in affordable healthcare and India's self-sufficiency in clinical development.

KIIT School of Biotechnology hosted the 10th Biotech Industrial Conclave on 'Biotechnology for Humanity: Innovations Shaping a Better World' on August 23-24, 2024, featuring discussions on industry-academia collaboration, emerging trends in biotech, and the role of startups. Key speakers included Dr. Achyuta Samanta, Dr. Krishna Ella, and various industry experts, focusing on topics like vaccine development, molecular diagnostics, and food safety.

Hilleman Laboratories' partner Bharat Biotech launched Hillchol oral cholera vaccine, using a single, genetically engineered Hikojima strain. Approved in India, Bharat Biotech aims for WHO prequalification for global distribution. The vaccine, developed through collaboration, addresses global cholera vaccine shortages.